Three FDA databases show approval. Registration and NDC numbers do not

ON THIS PAGE

1. Key findings
2. Drugs@FDA: approved drugs, with one large gap
3. The Orange Book: approved drugs and their generics
4. The Purple Book: licensed biological products
5. What registration, listing and an NDC number do not mean
6. Two lookups, run on October 22, 2026
7. Limitations
8. Sources

Whether a compound is an FDA-approved drug has a lookup answer. FDA publishes three databases that hold it, and each one covers a different set of products.

A fourth kind of record looks official and is not approval at all: a registration, a drug listing or a National Drug Code (NDC) number. FDA says so in plain words. A seller's page that leans on any of those has shown that paperwork was filed, nothing more.

Drugs@FDA: approved drugs, with one large gap

Drugs@FDA is the broadest place to start. Its own page, read on October 22, 2026, says it "includes information about drugs, including biological products, approved for human use in the United States." The same sentence sets the limit. It "does not include information about FDA-approved products regulated by the Center for Biologics Evaluation and Research," and names vaccines, allergenic products, blood products, plasma derivatives and cell and gene therapies as examples.

For a prescription brand-name drug, the page says Drugs@FDA "typically includes the most recent labeling approved by the FDA," along with regulatory information and FDA staff reviews. Each record sits under an application number. An NDA is a new drug application. An ANDA is an abbreviated new drug application.

A missing record here is a strong signal. It is not the last word for a vaccine or a blood product, which live elsewhere.

The Orange Book: approved drugs and their generics

The Orange Book answers a narrower question. FDA's Orange Book page (content current as of October 13, 2026, read October 22, 2026) says it "identifies drug products approved on the basis of safety and effectiveness by the Food and Drug Administration (FDA) under the Federal Food, Drug, and Cosmetic Act (the Act) and related patent and exclusivity information."

Two things set it apart. Each product carries a marketing status, such as Prescription or Discontinued. Each also carries a therapeutic equivalence code. The Sandostatin entries checked below carry the code AP. A discontinued entry is still an approval on record. It just is not being sold.

The Purple Book: licensed biological products

The Purple Book covers biologics, which are licensed rather than approved under a drug application. Its About page, read on October 22, 2026, says it "is a database that contains information about all FDA-licensed biological products regulated by the Center for Drug Evaluation and Research (CDER), including licensed biosimilar and interchangeable products, and their reference products." It also covers the vaccine, blood, allergenic and cell and gene therapy products that Drugs@FDA leaves out.

Where a peptide lands depends on its size. Federal rule 21 CFR 600.3(h)(6), read on eCFR on October 22, 2026, defines a protein as "any alpha amino acid polymer with a specific, defined sequence that is greater than 40 amino acids in size." A protein is regulated as a biologic. A peptide at or under that size is regulated as a drug, so its approval, if it has one, sits in Drugs@FDA and the Orange Book. Searching the Purple Book for a short peptide and finding nothing proves nothing.

What registration, listing and an NDC number do not mean

This is where an official-looking record and an approval part ways. Companies that make drugs for sale in the United States must register their sites with FDA and list each drug they make. FDA's page on drug registration and listing (content current as of February 5, 2026, read October 22, 2026) says: "Registering an establishment and listing drugs with FDA does not indicate the products are approved or that FDA has verified the information provided."

FDA's National Drug Code Directory page (content current as of March 4, 2026, read October 22, 2026) goes further. It says the directory holds "approved and unapproved drugs." It also says:

• "Assignment of an NDC number does not in any way denote FDA approval of the product."
• "Any representation that creates an impression of FDA approval because a product has an NDC number is misleading and violates federal law."
• "FDA does not submit or alter registration or listing data." The company that filed it is responsible for its accuracy.

So an NDC number on a label, or a line saying a site is "FDA registered," answers a different question. It says a filing exists. Only an approval record says FDA approved the drug.

Two lookups, run on October 22, 2026

Both examples are peptides. Octreotide acetate is a synthetic peptide with approved products on record. BPC-157 is the other.

On October 22, 2026, FDA's Drugs@FDA search page answered with a "confirm you're a human" check, so the searches were run in openFDA's drugsfda dataset instead. openFDA's own page names Drugs@FDA as the source of that data. Its copy was dated October 21, 2026.

The octreotide row shows what an approval looks like on paper: an application number, an applicant, a date and a status. The BPC-157 rows show the absence. In the FDA approval data searched on October 22, 2026, BPC-157 has no application record of any kind. It has no FDA approval for any use.

The empty Purple Book result for octreotide is the size rule at work. It is a peptide drug, so its records sit in the drug databases.

Limitations

The Drugs@FDA and Orange Book search forms both returned a human-verification check on the day of writing, so the Drugs@FDA lookups used openFDA's copy of the same data, and the BPC-157 search in the Orange Book was not completed. openFDA's own notice says its data should be assumed "unvalidated." A name search only finds what is spelled the way FDA spells it, so a missing result is strongest when several spellings come back empty, as they did here. These databases cover drugs and biologics for human use. Animal drugs are not in them. This piece is not legal advice.

The record either exists or it does not. A seller who claims approval can name the application number, and anyone can look it up.

Sources

All read 2026-10-22. FDA, Drugs@FDA: FDA-Approved Drugs, "About Drugs@FDA." FDA, Approved Drug Products with Therapeutic Equivalence Evaluations (Orange Book), content current as of 2026-10-13. FDA, Orange Book product page for application N019667. FDA, Purple Book, About; Purple Book search page showed its database dated 2026-09-30. FDA, Drug Registration and Listing System (DRLS and eDRLS), content current as of 2026-02-05. FDA, National Drug Code Directory, content current as of 2026-03-04. openFDA, Drugs@FDA API overview; queries run against api.fda.gov/drug/drugsfda.json, dataset dated 2026-10-21. 21 CFR 600.3(h)(6), definition of protein, read on ecfr.gov (current through 2026-10-20).